Statistics for Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Total visits
| views | |
|---|---|
| Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. | 102 |
Total visits per month
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 1 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
File Visits
| views | |
|---|---|
| Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.pdf | 126 |
Top country views
| views | |
|---|---|
| Germany | 18 |
| United Kingdom | 9 |
| United States | 7 |
| Singapore | 3 |
| China | 2 |
| South Korea | 2 |
| Indonesia | 1 |
| Turkey | 1 |
Top city views
| views | |
|---|---|
| Kiez | 4 |
| Changi | 3 |
| Beijing | 2 |
| Seoul | 2 |
| Alexandria | 1 |
| Florence | 1 |
| Houston | 1 |
| Mountain View | 1 |
| Saint Louis | 1 |
| Tangerang | 1 |
| Yulee | 1 |